# OnCo record paper-pod1um-303-retifanlimab-anal-cancer-rao-lancet-2025 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-pod1um-303-retifanlimab-anal-cancer-rao-lancet-2025/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-pod1um-303-retifanlimab-anal-cancer-rao-lancet-2025" ;
  schema:name "POD1UM-303/InterAACT-2: retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic anal squamous cell carcinoma"@en ;
  schema:description "Adding the PD-1 antibody retifanlimab to first-line carboplatin and paclitaxel for advanced anal cancer lengthened the time before the cancer progressed from 7.4 to 9.3 months and cut the risk of progression by 37 percent, with manageable extra toxicity."@en ;
  schema:url <https://onco.cc/key-papers/paper-pod1um-303-retifanlimab-anal-cancer-rao-lancet-2025/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(25)00631-2>, <https://pubmed.ncbi.nlm.nih.gov/40517007/> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(25)00631-2> ;
  schema:datePublished "2025"^^xsd:gYear ;
  schema:author "Rao S, Samalin-Scalzi E, Evesque L, et al." ;
  onco:cancers <https://onco.cc/cancers/metastatic-anal-cancer/>, <https://onco.cc/cancers/anal/> ;
  onco:drugs <https://onco.cc/drugs/retifanlimab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/> ;
  onco:trials <https://onco.cc/trials/pod1um-303/> ;
  onco:journals <https://onco.cc/journals/lancet/> .